



Journal of Controlled Release Vol. 220, 2015

Contents

COVER STORY

Novel approach to measure drug release from nanomedicines

Kinam Park


p 568

REVIEWS

Genetically engineered mesenchymal stem cell therapy using self-assembling supramolecular hydrogels

Byung Woo Hwang, Su Jin Kim, Kyeng Min Park, Hyemin Kim, Junseok Yeom, Jeong-A Yang, Hyeonseon Jeong, Hyuntae Jung, Kimoon Kim*, Young Chul Sung**, Sei Kwang Hahn***


pp 119–129



Bridging small interfering RNA with giant therapeutic outcomes using nanometric liposomes

Yuvraj Singh, Sandeep Tomar, Shariq Khan, Jaya Gopal Meher, Vivek K. Pawar, Kavita Raval, Komal Sharma, Pankaj K. Singh, Mohini Chaurasia, B. Surendar Reddy, Manish K. Chourasia*


pp 368–387



Engineered *in-situ* depot-forming hydrogels for intratumoral drug delivery

pp 465–475


Amir Fakhari, J. Anand Subramony*

**RESEARCH PAPERS****Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates**

pp 5–17

Yuqin Yao, Lin Yu, Xiaolan Su, Yuxi Wang, Wenting Li, Yangpin Wu, Xiangzheng Cheng, Hang Zhang, Xian Wei, Hao Chen, Rundong Zhang, Lantu Gou, Xiaoxin Chen, Yongmei Xie*, Bo Zhang, Yonghui Zhang, Jinliang Yang*, Yuquan Wei


Schematic displays the structures of three HER2-targeting antibody-drug conjugates (ADCs): T-SN38 A prepared with the hydrophobic ester linkage linker A which contained ester bond cleavage site; T-SN38 B contains hydrophobic linker B with carbonate cleavage site; T-SN38 C contains linker C with hydrophilic PEG4 fragment and carbonate cleavage site. Results of *in vitro* and *in vivo* showed T-SN38 A, B and C (Drug Antibody Ratio, DAR = 3.7, 3.2, 3.4) have great potential for HER2-positive ovarian cancer.

**A bacterial protease inhibitor protects antigens delivered in oral vaccines from digestion while triggering specific mucosal immune responses**

pp 18–28


Andrés Esteban Ibañez, Lorena Mirta Coria, Marianela Verónica Carabajal, María Victoria Delpino, Gabriela Sofia Risso, Paula Gonzalez Cobiello, Jimena Rinaldi, Paula Barrionuevo, Laura Bruno, Fernanda Frank, Sebastián Klinke, Fernando Alberto Goldbaum, Gabriel Briones, Guillermo Hernán Giambartolomei, Karina Alejandra Pasquevich, Juliana Cassataro*

Oral co-administration of the antigen (Ag) with a bacterial protease inhibitor: i) increases the half-life of the Ag by inhibiting gastrointestinal proteases, ii) induces recruitment, activation and Ag internalization by dendritic cells and consequently iii) mucosal and systemic Ag-specific immune responses are enhanced.

**Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed**

pp 29–36

Hidenori Ando, Sakiko Kobayashi, Amr S. Abu Lila, Noha Essam Eldin, Chihiro Kato, Taro Shimizu, Masami Ukawa, Kazuyoshi Kawazoe, Tatsuhiro Ishida*



Download English Version:

<https://daneshyari.com/en/article/10612722>

Download Persian Version:

<https://daneshyari.com/article/10612722>

[Daneshyari.com](https://daneshyari.com)